Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 18, 2008 - Issue 11
Submit an article Journal homepage
49
Views
1
CrossRef citations to date
0
Altmetric
Patent Evaluations

Multiple-delayed release formulation approach for the treatment of methicillin-resistant Staphylococcus aureus

Michio Kurosu Colorado State University, College of Veterinary Medicine and Biomedical Sciences, Department of Microbiology, Immunology, and Pathology, 1682 Campus Delivery, Fort Collins, CO 80523-1682, Colorado, USA +1 970 491 7628; [email protected]
Pages 1313-1319 | Published online: 29 Oct 2008

Bibliography

  • Renet K, Guillemot D, Jarlier V, et al. Antibacterial resistance, Wayampis Amerindians, French Guyana. Emerg Infect Dis 2004;10:1150-4
  • Cosgrove SE, Fowler VG. Management of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:S386-93
  • Cunha BA. Vancomycin revisited: a reappraisal of clinical use. Crit Care Clin 2008;24:393-420
  • Loffler CA, MacDougall C. Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections. Expert Rev Anti Infect Ther 2007;5:961-81
  • Tacconelli E, Cataldo MA. Antimicrobial therapy of Staphylococcus aureus bloodstream infection. Expert Opin Pharmacother 2007;8:2505-18
  • Klevens RM, Edwards JR, Tenover FC, et al. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis 2006;42:389-91
  • Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Healthcare Epidemiol 2005;41:848-54
  • Kluytmans-Vandenbergh MFQ, Kluytmans JAJW. Community-acquired methicillin-resistant Staphylococcus aureus: current perspectives. Clin Microbiol Infec 2006;12:9-15
  • Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 2007;13:1840-6
  • Eady EA, Cove JH. Staphylococcal resistance revisited: community-acquired methicillin-resistant Staphylococcus aureus – an emerging problem for the management of skin and soft tissue infections. Curr Opin Infect Dis 2003;16:103-24
  • Diederen BMW, Kluytmans JAJW. The emergence of infections with community-associated methicillin resistant Staphylococcus aureus. J Infect 2006;52:157-68
  • Barbachyn MR, Ford CW. Oxazolidinone structure-activity relationships leading to linezolid. Angew Chem Int Engl 2003;42:2010-23
  • Wilcox MH. Update on linezolid: the first oxazolidinone antibiotic. Expert Opin Pharmacother 2005;6:2315-26
  • Schentag JJ, Hyatt JM, Carr JR, et al. Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control. Clin Infect Dis 1998;26:1204-14
  • Donadio S, Soiso M. Biosynthesis of glycopeptides: prospects for improved antibacterials. Curr Top Med Chem 2008;8:654-66
  • Pace JL, Yang G. Glycopeptides: update on an old successful antibiotic class. Biochem Pharmacol 2006;71:968-80
  • Gales AC, Sader HS, Andrade SS, et al. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in patient with cysteic fibrosis. Int J Antimicrob Agents 2007;27:300-2
  • Schmidt-Ioanas M, De Roux A, Lode H. New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient. Curr Opin Crit Care 2005;11:481-6
  • Henck J-O, Byrrn SR. Designing a molecular delivery system within a preclinical timeframe. Drug Discov Today 2007;12:189-99
  • Anonymous: amoxicillin pulsatile MiddleBrook: APC 111, APC-111, PULSYS-enhanced amoxicillin. Drugs in R D 2007;8:395-9
  • Rayner C, Munchhof WJ. Antibiotics currently used in the treatment of infections caused Staphylococcus aureus. Int Med J 2005;35:S3-16
  • Gosbell IB. Methicillin-resistant Staphylococcus aureus: impact on dermatology practice. Am J Clin Dermatol 2004;5:239-59
  • Batts DH, Dekoning TF. Combination of Gyrase B inhibitors and protein synthesis inhibitors and uses thereof. WO2007142725; 2007
  • Srinivas J. Formulation comprising of ceftazidime, tazobactam and linezolid. PCT Int. Appl; 2007. p. 21
  • Graham S, Coote PJ. Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin. J Antimicrob Chemother 2007;59:759-62
  • Jacqueline C, Navas D, Batard E, et al. In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus. Antimicro Agents Chemother 2005;49:45-51
  • Nagasawa Z, Kusaba K, Takayanagi M, et al. Detection method of β-lactam antibiotic induced vancomycin-resistant MRSA and combined effects of antibiotics against MRSA. Nippon Kagaku Ryoho Gakkai Zasshi 2003;51:631-7
  • Pexher JC, Tancrede C, Tancrede D. In vitro study of the bactericidal activity of a sulfamethoxazole-trimethoprim combination of 59 hospital strains. Therapie 1970;25:13-28
  • Schiraldi O, Sforza E, Piaia F. Effect of a new sulfa- trimethoprim combination (trimethoprim -sulfamethopyrazine) in typhoid fever. A double-blind study on 72 adult patients. Chemotherapy 1985;31:68-75
  • Bohni E. Comparative bacteriological investigations with the combination trimethoprim/sulfamethoxazole in vitro and in vivo. Chemotherapy 1969;14:1-21
  • Miyamoto E. Oral trimethoprim-sufamethoxazole for methicillin-resistant Staphylococcus aureus infections: the evidence behind the use.Drug Ther Topics 2004;33:69-74
  • Roccaforte JS, Bittner MJ, Stumpf CA, Preheim LC. Attempts to eradicate methicillin-resistant Staphylococcus aureus colonization with the use of trimethoprim-sulfamethoxazole, rifampin, and bacitracin. Am J Infect Control 1988;16:141-6
  • Hoffman A, Horwitz E, Hess S, et al. Implications on emergence of antimicrobial resistance as a critical aspect in the design of oral sustained release delivery systems of antimicrobials. Pharm Res 2008;25:667-71
  • Anal AK. Time-controlled pulsatile delivery system for bioactive compounds. Recent Patents Drug Deliv Formulation 2007;1:73-9
  • Maroni A, Zema L, Cerea M, Sangalli ME. Oral pulsatile drug delivery systems. Expert Opin Drug Deliv 2005;2:855-71
  • Bussemer T, Bodmeier R. A review of pulsatile drug delivery. Am Pharm Rev 2001;4:18-22
  • Bussemer T, Otto I, Bodmeier R. Pulsatile drug-delivery systems. Crit Rev Ther Drug 2001;18:433-58
  • Makino K. Time-controlled drug release devices. Farumashia 2001;37:382-4
  • Kikuchi A, Okano T. Pulsatile drug release control using hydrogels. Adv Drug Deliver Rev 2002;54:53-77
  • Available from: www.eurand.com
  • Liu J, Ren HP. Tuberculosis: current treatment and new drug development. Anti-Infect. Agents Med Chem 2006;5:331-44
  • Conley C, Roush J, Storm K. Once daily dosing formulations for amoxicillin and clavulanic acid. PCT Int. Appl; 2002. p. 28
  • New HC. Synergy and antagonism of combinations with quinolones. Eur J Clin Microbiol Infect Dis 1991;10:255-61
  • Holm SE. Interaction between β-lactam and other antibiotics. Reviews Infect Dis 1986;8:S305-14
  • Giddens SR, Bean DC. Investigations into the in vitro antimicrobial activity and mode of action of the phenazine antibiotic D-alanylgriseluteic acid. Int J Antimicro Agents 2007;29:93-7
  • Price-Whelan A, Dietrich LEP, Newman DK. Rethinking secondary metabolism: physiological roles for phenazine antibiotics. Nature Chem Biol 2006;2:71-8
  • Feldman AR, Lee J, Delelmas B, Paetzel M. Crystal structure of a novel viral protease with a serine/lysine catalytic dyad mechanism. J Mol Biol 2006;358:1378-89
  • Cirz RT, Romesberg FE. Induction and inhibition of ciprofloxacin resistance-conferring mutations in hypermutator bacteria. Antimicrob Agents Chemother 2006;50:220-5
  • Da Cunha EFF, Ramalho TC, Maia ER, De Alencastro RB. The search for new DHFR inhibitors: a review of patents January 2001-February 2005. Expert Opin Ther Patents 2005;15:967-86
  • Hawser S, Lociuro S, Islam K. Dihydrofolate reductase inhibitors as antibacterial agents. Biochem Pharmacol 2006;71:941-8

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.